Staphylococcus aureus pneumonia

Summary

Staphylococcus aureus pneumonia (MONDO:0041879) is a disease and 5 clinical trials. Top therapeutic interventions include suvratoxumab and tosatoxumab. A subtype of staphylococcus aureus infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	staphylococcus aureus pneumonia
Mondo ID	MONDO:0041879
ICD-10-CM	J15.21
SNOMED CT	441658007
UMLS	C0857862
MedGen	167803
Is cancer (heuristic)	no

Also known as: pneumonia due to staphylococcus aureus · Staphylococcus aureus caused pneumonia · Staphylococcus aureus pneumonia · staphylococcus aureus pneumonia

Disease family

This is a subtype of staphylococcus aureus infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › staphylococcal infection › staphylococcus aureus infection › staphylococcus aureus pneumonia

Related subtypes (6): impetigo, hordeolum, staphylococcal scalded skin syndrome, methicillin-resistant staphylococcus aureus infectious disease, methicillin-susceptible staphylococcus aureus infectious disease, staphylococcus discitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01589185	PHASE1/PHASE2	COMPLETED	Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)
NCT02296320	PHASE2	COMPLETED	Study of the Efficacy and Safety of MEDI4893
NCT02798497	Not specified	COMPLETED	Panton Valentine Leucocidin
NCT03367624	Not specified	UNKNOWN	Epidemiology of Post-influenza Bacterial Pneumonia Due to a Panton-Valentine Leukocidin Positive Staphylococcus Aureus
NCT04171583	Not specified	COMPLETED	Mucoid Staphylococcus Aureus in Cystic Fibrosis Airways

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SUVRATOXUMAB	3	1
TOSATOXUMAB	3	1